NYSEAMERICAN:DXRDaxor Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Daxor Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.96 +1.29 (+8.79 %) (As of 07/2/2020 04:00 PM ET) Add Compare Share Today's Range$14.71Now: $15.96▼$17.0050-Day Range N/A52-Week Range$7.77Now: $15.96▼$17.90Volume10,800 shsAverage Volume16,265 shsMarket Capitalization$62.07 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingDaxor has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Daxor has a potential upside of 25.3% from its current price of $15.96.Amount of Analyst CoverageDaxor has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesDaxor has received 152 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDaxor has received 139 “underperform” votes. (Add your “underperform” vote.)Community SentimentDaxor has received 52.23% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Daxor and other stocks. Vote “Outperform” if you believe DXR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DXR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDaxor does not currently pay a dividend.Dividend GrowthDaxor does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Daxor insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.17 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Medical Instruments & Supplies Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:DXR Previous SymbolNYSE:DXR CUSIPN/A CIK27367 Webwww.daxor.com Phone+1-212-3308500Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares3,889,000Market Cap$62.07 million Next Earnings DateN/A OptionableNot Optionable AMEX:DXR Rates by TradingView Receive DXR News and Ratings via Email Sign-up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter. Daxor (NYSEAMERICAN:DXR) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Daxor? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daxor in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Daxor. What price target have analysts set for DXR? 2 brokers have issued 12 month price targets for Daxor's shares. Their forecasts range from $18.00 to $22.00. On average, they expect Daxor's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 25.3% from the stock's current price. View analysts' price targets for Daxor. Has Daxor been receiving favorable news coverage? Press coverage about DXR stock has been trending negative recently, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Daxor earned a daily sentiment score of -2.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the near term. View the latest news about Daxor. Are investors shorting Daxor? Daxor saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 29,000 shares, an increase of 5.1% from the May 31st total of 27,600 shares. Based on an average daily trading volume, of 16,600 shares, the short-interest ratio is presently 1.7 days. Currently, 3.5% of the shares of the stock are sold short. View Daxor's Current Options Chain. Who are some of Daxor's key competitors? Some companies that are related to Daxor include Bovie Medical (BVX), CRH Medical (CRH), Tristel (TSTL), Retractable Technologies (RVP), CRH Medical (CRHM), CRH Medical (CRHM), SDI (SDI), Milestone Scientific (MLSS), Omega Diagnostics Group (ODX), IsoRay (ISR), IsoRay (ISR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV) and TransEnterix (TRXC). View all competitors. What other stocks do shareholders of Daxor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Pfizer (PFE), ContraFect (CFRX), Dynavax Technologies (DVAX), Micron Technology (MU), Sanofi (SNY), Verastem (VSTM) and Cidara Therapeutics (CDTX). Who are Daxor's key executives? Daxor's management team includes the following people: Mr. Michael Richard Feldschuh, Chairman, Pres & CEO (Age 50)Mr. Jonathan Adam Feldschuh, Chief Scientific Officer & Director (Age 54)Mr. Robert J. Michel CPA, Chief Financial Officer (Age 62)Ms. Kathryn A. Kornafel, VP of Marketing & Commercial Devel.Mr. Guido Manzo, VP of Sales What is Daxor's stock symbol? Daxor trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "DXR." How do I buy shares of Daxor? Shares of DXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Daxor's stock price today? One share of DXR stock can currently be purchased for approximately $15.96. How big of a company is Daxor? Daxor has a market capitalization of $62.07 million. What is Daxor's official website? The official website for Daxor is www.daxor.com. How can I contact Daxor? Daxor's mailing address is 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States. The company can be reached via phone at +1-212-3308500. This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
